Literature DB >> 35015893

PLK inhibitors come of age in pediatric brain tumors.

Shinji Maegawa1, Vidya Gopalakrishnan2,3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35015893      PMCID： PMC8917393          DOI： 10.1093/neuonc/noab298

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  10 in total

Review 1.  The molecular classification of medulloblastoma: driving the next generation clinical trials.

Authors:  Sarah E S Leary; James M Olson
Journal:  Curr Opin Pediatr       Date:  2012-02       Impact factor: 2.856

2.  A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer.

Authors:  Peter M Ellis; Natasha B Leighl; Vera Hirsh; M Neil Reaume; Normand Blais; Rafal Wierzbicki; Behbood Sadrolhefazi; Yu Gu; Dan Liu; Korinna Pilz; Quincy Chu
Journal:  Clin Lung Cancer       Date:  2015-06-02       Impact factor: 4.785

3.  Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.

Authors:  Daibiao Xiao; Ming Yue; Hexiu Su; Ping Ren; Jue Jiang; Feng Li; Yufeng Hu; Haining Du; Hudan Liu; Guoliang Qing
Journal:  Mol Cell       Date:  2016-10-20       Impact factor: 17.970

4.  Medulloblastoma comprises four distinct molecular variants.

Authors:  Paul A Northcott; Andrey Korshunov; Hendrik Witt; Thomas Hielscher; Charles G Eberhart; Stephen Mack; Eric Bouffet; Steven C Clifford; Cynthia E Hawkins; Pim French; James T Rutka; Stefan Pfister; Michael D Taylor
Journal:  J Clin Oncol       Date:  2010-09-07       Impact factor: 44.544

5.  Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients?

Authors:  Vijay Ramaswamy; Marc Remke; Jennifer Adamski; Ute Bartels; Uri Tabori; Xin Wang; Annie Huang; Cynthia Hawkins; Donald Mabbott; Normand Laperriere; Michael D Taylor; Eric Bouffet
Journal:  Neuro Oncol       Date:  2015-01-20       Impact factor: 12.300

Review 6.  Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.

Authors:  Rosie Elizabeth Ann Gutteridge; Mary Ann Ndiaye; Xiaoqi Liu; Nihal Ahmad
Journal:  Mol Cancer Ther       Date:  2016-06-21       Impact factor: 6.261

7.  Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients.

Authors:  Christin Schmidt; Nil A Schubert; Sebastian Brabetz; Norman Mack; Benjamin Schwalm; Jennifer A Chan; Florian Selt; Christel Herold-Mende; Olaf Witt; Till Milde; Stefan M Pfister; Andrey Korshunov; Marcel Kool
Journal:  Neuro Oncol       Date:  2017-11-29       Impact factor: 12.300

8.  A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy.

Authors:  Dong Wang; Bethany Veo; Angela Pierce; Susan Fosmire; Krishna Madhavan; Ilango Balakrishnan; Andrew Donson; Irina Alimova; Kelly D Sullivan; Molishree Joshi; Mark Erlander; Maya Ridinger; Nicholas K Foreman; Sujatha Venkataraman; Rajeev Vibhakar
Journal:  Neuro Oncol       Date:  2022-03-12       Impact factor: 13.029

9.  Epigenetic activation of a RAS/MYC axis in H3.3K27M-driven cancer.

Authors:  Sanja Pajovic; Robert Siddaway; Taylor Bridge; Javal Sheth; Patricia Rakopoulos; Byungjin Kim; Scott Ryall; Sameer Agnihotri; Lauren Phillips; Man Yu; Christopher Li; Scott Milos; Palak Patel; Dilakshan Srikanthan; Annie Huang; Cynthia Hawkins
Journal:  Nat Commun       Date:  2020-12-04       Impact factor: 14.919

10.  A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia.

Authors:  Amer M Zeidan; Maya Ridinger; Tara L Lin; Pamela S Becker; Gary J Schiller; Prapti A Patel; Alexander I Spira; Michaela L Tsai; Errin Samuëlsz; Sandra L Silberman; Mark Erlander; Eunice S Wang
Journal:  Clin Cancer Res       Date:  2020-09-30       Impact factor: 12.531
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.